6 Dimensions Capital is set to exit immuno-oncology drug developer TCR² Therapeutics in an offering likely to raise between $70m and $80m.
TCR² Therapeutics, a US-based cancer immunotherapy developer backed by pharmaceutical firm WuXi AppTec, has set the terms for an initial public offering that would raise $80m at its upper end.
The company intends to issue 5 million shares on the Nasdaq Global Market priced between $14 and $16 per share, which would put the size of the offering at $70m to $80m. Unnamed shareholders have expressed interest in acquiring $30m of shares in the IPO.
TCR² is working on…
